Virtual Library
Start Your Search
T. Iriki
Author of
-
+
P3.15 - SCLC/Neuroendocrine Tumors (ID 731)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.15-009 - Impact of Interstitial Lung Disease on Clinical Outcomes in Small Cell Lung Cancer Patients (ID 8583)
09:30 - 09:30 | Author(s): T. Iriki
- Abstract
Background:
The impact of interstitial lung disease (ILD) on the clinical outcome in small cell lung cancer (SCLC) patients has not been fully understood. The purpose of this study is to investigate the impact of ILD on treatment and survival in SCLC.
Method:
From April 2006 to March 2016, 67 SCLC patients treated with chemotherapy at Kumamoto University hospital were evaluated. Therapeutic response, progression-free survival (PFS) and overall survival (OS) were compared between SCLC with ILD (n=16) and SCLC without ILD (n=51).
Result:
Patients’ characteristics including age, sex, smoking, serum LDH, stage (limited/ extensive disease) between two groups were similar, except for lower proportion of chemoradiotherapy in SCLC with ILD (7% vs. 57%, P= <0.001). SCLC with ILD had a significantly lower objective response rate than SCLC patients without ILD (50% vs. 84%, P= 0.005). SCLC patients with ILD had a significantly shorter PFS (median, 184 days vs. 290 days, P= 0.008) and OS (median, 241 days vs. 704 days, P= <0.001) than patients without ILD. In addition, multivariate analysis for PFS and OS revealed that the coexisting ILD was independent predictive factor for poor survival in SCLC patients treated with chemotherapy (PFS, hazard ratio [HR] 2.06, 95% confidence interval [CI], 1.01-4.18, P= 0.046, OS, HR 3.29, 95% CI 1.53-7.08, P= <0.002). Acute exacerbation of ILD was observed in 31% of SCLC patients with ILD.
Conclusion:
This study suggests that coexisting ILD is a predictive factor for poor PFS and OS in SCLC treated with chemotherapy.
